BackDrugs Made In America Acquisition Rights Overview

Drugs Made In America Acquisition Rights Receivables

Track Drugs Made In America Acquisition Rights's receivables ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Receivables
$0.00

Peer trimmed avg / median

Loading

Drugs Made In America Acquisition Rights Receivables History

Loading

Drugs Made In America Acquisition Rights vs. peers: Receivables Comparison

Loading

Drugs Made In America Acquisition Rights Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Drugs Made In America Acquisition Rights (DMAAR) FAQ

As of the most recent data (June 2026), DMAAR shows a receivables of $0. In the prior-year period, the figure was $0. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, DMAAR's receivables is now $0 (was $0). Pairing that YoY change with peer averages gives a clearer picture of whether Drugs Made In America Acquisition Rights is outperforming or lagging.

Tracking DMAAR's receivables over time shows whether Drugs Made In America Acquisition Rights is scaling, shrinking, or reshaping that part of the business. The current reading is $0 In the prior-year period, the figure was $0. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has Drugs Made In America Acquisition Rights's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $0) with ownership activity and broader fundamentals.